Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    xyz-pharma-2025-04-21

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    An Enquiry

    Menu

    Osilodrostat Phosphate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 10,750Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Recordati: FDA Expands Isturisa Indication for Cushing's Syndrome
    Recordati: FDA Expands Isturisa Indication for Cushing's Syndrome

    16 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/16/3062342/0/en/RECORDATI-FDA-GRANTS-ISTURISA-OSILODROSTAT-EXPANDED-INDICATION-FOR-THE-TREATMENT-OF-ENDOGENOUS-HYPERCORTISOLEMIA-IN-PATIENTS-WITH-CUSHING-S-SYNDROME.html

    GLOBENEWSWIRE
    16 Apr 2025
    Share Share
    Recordati Announce Publication of Outcomes From PIII LINC 3 Study of Isturisa
    Recordati Announce Publication of Outcomes From PIII LINC 3 Study of Isturisa

    31 Aug 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220830005004/en

    BUSINESSWIRE
    31 Aug 2022
    Share Share
    Phase III LINC 3 Study Says ISTURISA Shows Improvement in Cushing’s Disease
    Phase III LINC 3 Study Says ISTURISA Shows Improvement in Cushing’s Disease

    13 May 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220513005219/en

    BUSINESSWIRE
    13 May 2022
    Share Share
    Recordati: Positive Results From the PH III LINC-3 Study of Isturisa®
    Recordati: Positive Results From the PH III LINC-3 Study of Isturisa®

    27 Jul 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200727005863/en

    BUSINESSWIRE
    27 Jul 2020
    Share Share
    Recordati Rare Diseases: Isturisa® (osilodrostat) Phase III LINC-4 Trial
    Recordati Rare Diseases: Isturisa® (osilodrostat) Phase III LINC-4 Trial

    17 Jun 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200617005250/en

    BUSINESSWIRE
    17 Jun 2020
    Share Share
    Recordati Rare Diseases now holds Isturisa® European MA
    Recordati Rare Diseases now holds Isturisa® European MA

    08 Apr 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/04/08/2013471/0/en/Recordati-Rare-Diseases-now-holds-Isturisa-European-MA.html

    GLOBENEWSWIRE
    08 Apr 2020
    Share Share